FDA
Home Page | CDRH Home Page | Search
| CDRH
A-Z Index | Contact CDRH
|
This is a brief overview of information related to FDA's approval to market this product. See the links below to the Summary of Safety and Effectiveness and product labeling for more complete information on this product, its indications for use, and the basis for FDA's approval.
Product Name: Corometrics 120 F-Series Maternal/Fetal Monitor with
Integrated Fetal Oxygen Saturation Monitoring
Manufacturer: GE Medical Systems Information Technologies
Address: 61 Barnes Park Road North, Wallingford, CT
Approval Date: February 9, 2001
Approval Letter: http://www.fda.gov/cdrh/pdf/p000016a.pdf
What is it? This device is an electronic maternal/fetal monitor used during labor, with a new monitoring feature that continuously measures fetal oxygen saturation ("FSpO2"), the amount of oxygen in the blood of the fetus. The monitor also measures the fetus' heart rate and the contractions of the mother's uterus (womb). To make this new FSpO2 measurement, the Corometrics 120 F-Series monitor uses technology from Mallinckrodt's recently approved OxiFirstFetal Oxygen Saturation Monitoring System http://www.fda.gov/cdrh/mda/docs/p990053.html
How does it work? The OxiFirst sensor (Nellcor FS-14 sensor, in diagram above) is inserted through the mother's birth canal into the uterus (womb), where it rests against the cheek or temple of the fetus. Two light emitting diodes (LEDs) in the sensor shine light onto the skin of the fetus. The light reflects back to a photodetector (light-measuring device) in the sensor, and the photodetector signal is electronically processed to produce the FSpO2 measurement. The monitor can measure the oxygen saturation because blood rich in oxygen scatters back different-colored light than blood low in oxygen. The FSpO2 value is displayed continuously as a percentage on the monitor's front panel, along with other measurements. The doctor removes the OxiFirstsensor just before the baby is delivered.
When is it used? The OxiFirst sensor may be used with this monitor if the fetal heart rate pattern shows abnormalities that indicate the fetus may not be getting enough oxygen. It is intended for use only on single (not multiple) fetuses of at least 36 weeks of pregnancy, where the mother's water has broken, and the fetal head is in the normal, head-down, position for delivery. ;
What will it accomplish?
When should it not be used? Use of the fetal oxygen saturation monitoring feature is not recommended in patients with any of the following conditions:
Additional information:
Other: FDA's Office of Women's Health web site : http://www.fda.gov/womens/default.htm
Updated 7/11/01
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH